Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.55 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL452692 | 0.91 | ADORA1 (0.60) | ADORA1NR1H2SMN1; SMN2USP2ESR2 | |
| SCHEMBL3304724 | 0.91 | ADORA1 (0.60) | ADORA1NR1H2SMN1; SMN2USP2ESR2 | |
| SCHEMBL12923869 | 0.86 | ADORA1 (0.51) | ADORA1SMN1; SMN2USP2ESR2GPR119 | |
| SCHEMBL2081926 | 0.86 | ADORA1 (0.51) | ADORA1NR1H2SMN1; SMN2USP2ESR2 | |
| SCHEMBL16328025 | 0.82 | ADORA1 (0.56) | ADORA1NR1H2SMN1; SMN2USP2ESR2 | |
| SCHEMBL21005765 | 0.82 | ADORA1 (0.56) | ADORA1NR1H2SMN1; SMN2USP2ESR2 | |
| SCHEMBL2081909 | 0.81 | ADORA1 (0.50) | ADORA1NR1H2SMN1; SMN2ESR2GPR119 | |
| SCHEMBL25343515 | 0.81 | ADORA1 (0.51) | ADORA1NR1H2SMN1; SMN2USP2ESR2 | |
| SCHEMBL1934813 | 0.80 | ADORA1 (0.57) | ADORA1NR1H2SMN1; SMN2USP2ESR2 | |
| SCHEMBL6868401 | 0.80 | ADORA1 (0.56) | ADORA1NR1H2SMN1; SMN2USP2ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897595-B2 | Pyridoazepine derivatives | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-03-01 | — | — | US | disclosed |
| US-7897595-B2 | Pyridoazepine derivatives | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-03-01 | — | — | US | disclosed |
| US-7897595-B2 | Pyridoazepine derivatives | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-03-01 | — | — | US | disclosed |
| WO-2007140213-A1 | PYRIDOAZEPINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007140213-A1 | PYRIDOAZEPINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2007-12-06 | — | — | WO | disclosed |
| US-20070281918-A1 | PYRIDOAZEPINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2007-12-06 | — | — | US | disclosed |
| US-20070281918-A1 | PYRIDOAZEPINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2007-12-06 | — | — | US | disclosed |
| US-20070281918-A1 | PYRIDOAZEPINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281918-A1 | PYRIDOAZEPINE DERIVATIVES | HTR2C, HTR5A, HTR2A | ADORA1 91/4885NR1H2 2864/4885SMN1; SMN2 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.